Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis

2025/08/05 by Andreas Kerschbaumer, Marlene Steiner, Pascale Pruckner +5 · 1 voice
Immunology and Microbiology · Medicine · #Biomedical Ethics and Regulation #Biosimilars and Bioanalytical Methods #Ethics in Clinical Research

paper · doi:10.1016/j.ard.2025.07.010

openalex publication_date 2025/08/05 · crossref created 2025/08/05 · crossref issued 2025/10/01 · crossref published 2025/10/01 · crossref published-print 2025/10/01 · openalex created_date 2025/10/10 · crossref deposited 2026/04/26 · crossref indexed 2026/07/17 · openalex updated_date 2026/07/18

Citations

• Inequities in access to biologic and synthetic DMARDs across 46 European countries
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Discussions

• Two new papers from our division show that recruiting RA & PsA trial patients in less affluent regions increase placebo rates - likely from limited treatment access. Trial design must adapt. RA: doi.o [bsky, 0 points, 0 comments]